TALAPRO-2 final data: a win for BRCA+... - Fight Prostate Ca...

Fight Prostate Cancer

2,985 members1,361 posts

TALAPRO-2 final data: a win for BRCA+ mCRPC, less positive data for other HRR mutations (like my ATM)

Maxone73 profile image
3 Replies

Ok, now I would LOVE to see the same trial using the new parp inhibitor saruparib , which is considered waaaaay less toxic and more targeted compared to the others, but…

The TALAPRO-2 trial confirmed that talazoparib + enzalutamide significantly improves overall survival (OS) in HRR-deficient mCRPC, with BRCA1/2-mutated patients seeing the greatest benefit. Their median OS was not reached, compared to 28.5 months with enzalutamide alone. For non-BRCA HRR mutations, the 10-month OS improvement (42.4 vs. 32.6 months) showed a positive trend but was not statistically significant yet (a bigger sample is probably needed). The findings reinforce HRR testing as critical for treatment selection, solidifying PARP inhibition as a key strategy in BRCA1/2-driven mCRPC. The trend looks positive also for the other HRR mutations but further research is needed to confirm it.

prostatewarriors.com/2025/0...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
3 Replies
KocoPr profile image
KocoPr

this Saruparib trial results interest me on this specific PARP1 inhibitor.

Phase III meaning it is close to be approved.

chatGPT;

• EvoPAR-Prostate01 Trial: A Phase III, double-blind, placebo-controlled study assessing saruparib in combination with physician’s choice of new hormonal agents (NHAs) in men with metastatic castration-sensitive prostate cancer (mCSPC). The trial includes two cohorts based on homologous recombination repair mutation (HRRm) status, aiming to evaluate the efficacy of saruparib plus NHA versus placebo plus NHA

Maxone73 profile image
Maxone73 in reply toKocoPr

One of the doctor I talked to is the chief of saruparib trial in whole Italy. He disappointed me when he said that the current trial don't include ATM mutations yet, but when I asked if saruparib was performing well he said he could not say anything yet and that I had to interpret his non verbal language. Then he looked at me with a big smile! 😂😂

KocoPr profile image
KocoPr in reply toMaxone73

When i used to travel for work in diff countries and didn’t know the language i just always smiled and that always got good vibes back. So the smile IS the international language.

Not what you're looking for?

You may also like...

FDA Grants Priority Review to Olaparib for HRR-Mutant mCRPC - Targeted Oncology - January 20, 2020

The FDA has granted a Priority Review to the New Drug Application for olaparib (Lynparza) as...
cujoe profile image

BCR May Not Be a Strong Surrogate End Point for Prostate Cancer Survival

A new study, below [1] & [2]. In 2004 I came across old studies that showed that ADT promotes...
pca2004 profile image

EMBARK Study: Enzalutamide +/- ADT

Results of the EMBARK study was published this week (10/19/23) in NEJM. It compared high risk BCR...

Determinants of PSA Response to Bipolar Androgen Therapy [BAT]

New study from Sartor et al below [1]. "Bipolar Androgen Therapy (BAT) is a novel therapy known to...
pjoshea13 profile image

Why we add an AART drug to ADT?

In response to a post asking if adding enzalutamide to ADT is beneficial: Xtandi would increase T...
MateoBeach profile image